PriceTargets.com logo

NASDAQ:MRNS - Marinus Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $34.60
  • Forecasted Upside: 271.64 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$9.31 As of 12/3/2021 05:00 PM ET
▼ -1.01 (-9.79%)

This chart shows the closing price for MRNS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Marinus Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MRNS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MRNS

Analyst Price Target is $34.60
▲ +271.64% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Marinus Pharmaceuticals in the last 3 months. The average price target is $34.60, with a high forecast of $40.00 and a low forecast of $23.00. The average price target represents a 271.64% upside from the last price of $9.31.

This chart shows the closing price for MRNS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 investment analysts is to buy stock in Marinus Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2021

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/18/2021SVB LeerinkReiterated RatingOutperformHigh
10/5/2021JMP SecuritiesReiterated RatingBuy$23.00Low
9/20/2021JMP SecuritiesReiterated RatingBuy$23.00High
8/30/2021JMP SecuritiesReiterated RatingBuy$23.00Medium
8/19/2021Robert W. BairdReiterated RatingBuy$32.00High
8/19/2021SVB LeerinkReiterated RatingBuyHigh
8/18/2021Truist SecuritiesBoost Price TargetBuy$35.00 ➝ $40.00High
8/18/2021TruistBoost Price TargetBuy$35.00 ➝ $40.00High
8/17/2021Cantor FitzgeraldReiterated RatingOverweightHigh
5/20/2021Robert W. BairdReiterated RatingBuy$32.00Medium
3/10/2021HC WainwrightBoost Price TargetBuy$35.00 ➝ $38.00Medium
11/10/2020Cantor FitzgeraldBoost Price TargetOverweight$8.00 ➝ $27.00Low
9/30/2020TruistInitiated CoverageBuy$35.00High
9/28/2020HC WainwrightBoost Price TargetBuy$9.00 ➝ $35.00Low
9/25/2020LADENBURG THALM/SH SHReiterated RatingBuy$20.00High
9/25/2020JMP SecuritiesBoost Price TargetPositive ➝ Outperform$7.00 ➝ $26.00High
9/23/2020OppenheimerBoost Price TargetOutperform$7.00 ➝ $28.00N/A
9/15/2020JMP SecuritiesBoost Price Target$28.00 ➝ $16.00Low
9/15/2020OppenheimerBoost Price TargetPositive ➝ Outperform$24.00 ➝ $28.00High
9/15/2020SVB LeerinkBoost Price TargetOutperform$24.00 ➝ $32.00High
9/15/2020HC WainwrightReiterated RatingBuy$36.00High
9/15/2020Cantor FitzgeraldBoost Price TargetOverweight$24.00 ➝ $32.00High
9/15/2020Jefferies Financial GroupBoost Price TargetBuy$16.00 ➝ $24.00High
9/8/2020OppenheimerReiterated RatingBuy$24.00Low
8/7/2020OppenheimerReiterated RatingBuy$24.00Medium
8/6/2020LADENBURG THALM/SH SHReiterated RatingBuy$18.00Medium
7/1/2020CowenInitiated CoverageOutperformMedium
6/30/2020HC WainwrightReiterated RatingBuy$24.00 ➝ $36.00High
5/5/2020Cantor FitzgeraldLower Price TargetOverweight$28.00 ➝ $24.00High
5/5/2020HC WainwrightReiterated RatingBuy$24.00High
4/9/2020Craig HallumInitiated CoverageBuy$18.00High
4/1/2020LADENBURG THALM/SH SHReiterated RatingBuy$20.00High
1/10/2020HC WainwrightBoost Price TargetBuy$20.00 ➝ $24.00Medium
12/19/2019OppenheimerInitiated CoverageOutperform$24.00High
11/18/2019LADENBURG THALM/SH SHReiterated RatingBuy$20.00High
11/13/2019HC WainwrightReiterated RatingBuy$20.00Low
10/18/2019HC WainwrightSet Price TargetBuy$20.00N/A
10/18/2019Cantor FitzgeraldReiterated RatingOverweight$28.00Medium
9/26/2019LADENBURG THALM/SH SHReiterated RatingBuy$20.00High
9/3/2019HC WainwrightInitiated CoverageBuy$20.00High
8/9/2019LADENBURG THALM/SH SHReiterated RatingBuy$12.00Low
7/25/2019LADENBURG THALM/SH SHReiterated RatingBuy$12.00High
7/23/2019MizuhoLower Price TargetNeutral$20.00 ➝ $6.80N/A
5/1/2019Cantor FitzgeraldReiterated RatingBuy$88.00High
5/1/2019LADENBURG THALM/SH SHReiterated RatingBuy$98.00High
3/5/2019Jefferies Financial GroupInitiated CoverageBuy$14.00 ➝ $40.00High
2/27/2019MizuhoDowngradeBuy ➝ Neutral$52.00 ➝ $20.00High
2/6/2019SVB LeerinkReiterated RatingOutperformHigh
12/26/2018Cantor FitzgeraldSet Price TargetBuy$88.00High
12/11/2018LADENBURG THALM/SH SHSet Price TargetBuy$88.00High
12/11/2018MizuhoReiterated RatingBuy$52.00Low
12/10/2018JMP SecuritiesBoost Price Target$116.00High
12/10/2018Cantor FitzgeraldSet Price TargetBuy$100.00High
12/4/2018Cantor FitzgeraldSet Price TargetBuy$76.00High
10/31/2018Cantor FitzgeraldSet Price TargetBuy$76.00Medium
9/25/2018MizuhoReiterated RatingBuy$52.00Medium
9/25/2018Cantor FitzgeraldSet Price TargetBuy$76.00High
9/17/2018Cantor FitzgeraldReiterated RatingBuy$76.00High
8/8/2018Cantor FitzgeraldSet Price TargetBuy$76.00Medium
8/2/2018MizuhoReiterated RatingBuy$52.00High
8/2/2018Cantor FitzgeraldReiterated RatingBuy$76.00High
7/2/2018Cantor FitzgeraldInitiated CoverageOverweight$76.00High
6/6/2018LADENBURG THALM/SH SHInitiated CoverageBuy$80.00High
5/23/2018Robert W. BairdInitiated CoverageOutperform$60.00High
4/19/2018MizuhoReiterated RatingBuy$52.00Low
3/19/2018MizuhoInitiated CoverageBuy ➝ Buy$52.00High
2/15/2018HC WainwrightInitiated CoverageBuy ➝ Buy$132.00High
12/14/2017LaidlawInitiated CoverageBuy ➝ Buy$72.00High
9/12/2017JMP SecuritiesReiterated RatingOutperform$20.00 ➝ $44.00High
(Data available from 12/4/2016 forward)

News Sentiment Rating

0.25 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2021
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/6/2021
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/5/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2021
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2021
  • 0 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2021

Current Sentiment

  • 0 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Marinus Pharmaceuticals logo
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.
Read More

Today's Range

Now: $9.31
Low: $9.27
High: $10.41

50 Day Range

MA: $11.72
Low: $9.31
High: $12.81

52 Week Range

Now: $9.31
Low: $9.27
High: $20.04

Volume

187,629 shs

Average Volume

127,568 shs

Market Capitalization

$342.33 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.16

Frequently Asked Questions

What sell-side analysts currently cover shares of Marinus Pharmaceuticals?

The following Wall Street sell-side analysts have issued reports on Marinus Pharmaceuticals in the last year: Cantor Fitzgerald, HC Wainwright, JMP Securities, Robert W. Baird, SVB Leerink LLC, Truist, Truist Securities, and Zacks Investment Research.
View the latest analyst ratings for MRNS.

What is the current price target for Marinus Pharmaceuticals?

5 Wall Street analysts have set twelve-month price targets for Marinus Pharmaceuticals in the last year. Their average twelve-month price target is $34.60, suggesting a possible upside of 271.6%. Truist has the highest price target set, predicting MRNS will reach $40.00 in the next twelve months. JMP Securities has the lowest price target set, forecasting a price of $23.00 for Marinus Pharmaceuticals in the next year.
View the latest price targets for MRNS.

What is the current consensus analyst rating for Marinus Pharmaceuticals?

Marinus Pharmaceuticals currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MRNS will outperform the market and that investors should add to their positions of Marinus Pharmaceuticals.
View the latest ratings for MRNS.

What other companies compete with Marinus Pharmaceuticals?

Other companies that are similar to Marinus Pharmaceuticals include ADC Therapeutics, Rocket Pharmaceuticals, ImmunoGen, Amarin, NGM Biopharmaceuticals, Myovant Sciences, Madrigal Pharmaceuticals, MorphoSys, Xenon Pharmaceuticals, Keros Therapeutics, uniQure, FibroGen, Amneal Pharmaceuticals, COMPASS Pathways and Organogenesis.

How do I contact Marinus Pharmaceuticals' investor relations team?

Marinus Pharmaceuticals' physical mailing address is 100 Matsonford Rd Suite 500, Radnor PA, 19087. The biopharmaceutical company's listed phone number is (484) 801-4670 and its investor relations email address is [email protected] The official website for Marinus Pharmaceuticals is www.marinuspharma.com.